ASELSAN signs three international agreements at MEDICA 2026 to scale medical-device exports
ASELSAN finalized three commercial agreements at MEDICA 2026 in Germany to broaden exports of domestically developed medical devices. The deals cover the HEARTLINE AED automated external defibrillator and the LIFELINE HLM heart‑lung machine, positioning Turkish engineering for rapid entry into multiple foreign markets. The partnerships with CITYCARE, MEDIAL GLOBAL and KOÇ MEDİKAL BIÇAKCILAR create distinct distribution channels for emergency cardiac devices and intraoperative life‑support systems.
LIFELINE HLM: two agreements creating access to 17 countries
ASELSAN reached separate agreements that together open access to 17 countries for the LIFELINE HLM cardiopulmonary bypass system. The first contract with MEDIAL GLOBAL covers distribution across 12 nations; the second with KOÇ MEDİKAL BIÇAKCILAR extends reach to five additional territories. These agreements establish regional commercialization frameworks—partner selection, regulatory pathway alignment, and logistics planning—without yet disclosing country lists or contract values.
How these agreements typically move from contract to delivered devices:
1) Regulatory mapping: partners map each target country’s medical device classification, required clinical evidence and notified body processes;
2) Technical transfer and training: ASELSAN supplies engineering documentation, maintenance protocols and hands‑on training for surgical and biomedical teams;
3) Pilot installations: initial hospital pilots validate integration with local clinical workflows and collect post‑market performance data;
4) Scale‑up and supply chain: partners finalize warehousing, spare parts stocking and authorized service networks to support routine and emergency needs;
Evaluating impact requires tracking milestone dates: regulatory approvals, pilot completions, purchase orders and delivery volumes. Until those milestones occur, treat the deals as commercial growth drivers rather than completed export shipments.
HEARTLINE AED: expanding presence in global emergency response
The agreement with France‑based CITYCARE covers sales of the HEARTLINE AED and related accessories. HEARTLINE devices analyze cardiac rhythm and decide whether to deliver a shock, offering both fully automatic and semi-automatic models. Key user features include voice and visual prompts, a metronome to guide chest compressions, and rapid charging to minimize downtime between shocks.
Concrete export performance to date: ASELSAN reports HEARTLINE has reached 26 countries with more than 13,000 units exported. That installed base supports two commercial advantages:
1. Field evidence for adoption: documented deployments in varied EMS and public settings create case studies for new customers.
2. Service and consumables demand: existing units generate ongoing sales of batteries, electrode pads and maintenance services—revenue streams that partners can forecast and scale.
Technical profile and clinical role of LIFELINE HLM
LIFELINE HLM functions as a cardiopulmonary bypass system used during open-heart surgery to temporarily maintain circulation and oxygenation. The device combines precision flow control, sensor‑based monitoring and automated calibration to support surgical teams with predictable hemodynamic management.
Notable technical elements that influence adoption and procurement:
• Closed‑loop flow control: reduces manual adjustments and stabilizes perfusion parameters during variable surgical conditions.
• Integrated sensors and alarms: continuous monitoring of pressures, temperatures and blood gases supports rapid clinical decision making.
• User‑centered interface: streamlined touchscreen workflows shorten setup and reduce training time for perfusionists.
Hospitals evaluating LIFELINE should run comparative bench tests and short‑term clinical pilots to measure oxygenator efficiency, prime volume, and consumable compatibility against incumbent systems.
Commercial and strategic implications for ASELSAN and Turkey’s medical sector
These agreements reflect a deliberate strategy: convert defense electronics and systems engineering capabilities into competitive medical devices and build export channels. Practical implications include:
• Export diversification: opening multiple country corridors reduces reliance on domestic sales cycles and clusters risk across different healthcare markets.
• After‑sales ecosystem: long‑term competitiveness depends on partner networks for parts, maintenance training and local technical support.
• Regulatory know‑how transfer: successful multi‑country launches require harmonized clinical evidence packages and spare submissions to national regulators or regional notified bodies.
Measure success by tracking the progression from signed agreements to regulatory approvals, pilot installations, purchase orders and cumulative unit shipments. Contract values and country lists, when announced, will provide the clearest short‑term economic signal.
What hospitals and partners should ask before adopting ASELSAN devices
Clinical and procurement teams should request precise documentation and commitments prior to procurement:
• Regulatory approvals and certificates: copies of CE, FDA or local registrations relevant to the purchaser’s country.
• Warranty, service response times and spare parts availability: service level agreements that define on‑site repair timelines and parts lead times.
• Training and competency programs: structured curricula for perfusionists, biomedical engineers and first responders, including hands‑on modules and refresher intervals.
• Clinical evidence: peer‑reviewed studies, post‑market surveillance data and pilot site outcomes demonstrating safety and efficacy.
Next steps and timeline expectations for the MEDICA 2026 agreements
Realistic timelines depend on each target country’s regulatory complexity and hospital procurement cycles. A conservative projection:
• 3–9 months: regulatory dossier preparation and initial submissions in easier jurisdictions;
• 6–18 months: pilot installations and local training in major hospital systems;
• 12–36 months: scaled deliveries and commercial rollouts across multiple hospitals within each partner’s territories.
Commercial partners will accelerate timelines by pre‑mapping regulations, committing local service teams, and coordinating logistics for initial pilot kits and consumable supply.
Bottom line: measured commercial expansion with practical next steps
ASELSAN’s MEDICA 2026 agreements create structured pathways for HEARTLINE AED and LIFELINE HLM to enter 17+ countries via established commercial partners. These deals reflect a shift from product development to international commercialization. Stakeholders should monitor regulatory milestones, pilot outcomes and early order books to assess the agreements’ conversion into sustained export revenue.